【Focus on IPO】New Dairy Industry’s Hong Kong IPO: Capital “Infusion” Doesn’t Hide Growth Anxiety; Regional Dairy Companies Face a Breakthrough Dilemma

Ask AI · Can listing on the Hong Kong Stock Exchange truly ease Synutra Dairy’s funding pressure?

By|Hengxin

Source|Bofang Finance

Recently, Synutra Dairy formally submitted an application for a main board listing on the Hong Kong Stock Exchange. JPMorgan Chase and Citic Securities will serve as joint sponsors. If the listing is successful, Synutra Dairy will become the first dairy products company in China to achieve a dual listing in both “A+H” locations.

However, the capital market has shown a lukewarm response to this “milestone”-style capital operation—one could even say it’s by “voting with its feet.”

As early as the day after Synutra Dairy disclosed its H-share listing plan on March 11, 2026, its A-share stock price promptly plunged by 9.21%, setting a new near-one-year high for the largest single-day decline. Within two trading days, its market value evaporated by more than RMB 1.7 billion.

This cold market reaction—like a bucket of cold water—has been poured over the grand narrative Synutra Dairy painted around its “internationalization strategy” and “building an international capital platform.”

Behind the polished prospectus is a harsh reality: revenue growth has nearly stalled, liabilities are high, goodwill is piling up, regional markets are imbalanced, and big players are circling.

As it heads to Hong Kong, one could say less that it is an active move for international expansion, and more that it is a passive “capital infusion” aimed at easing funding pressure and filling acquisition shortfalls.

01

The luster and shadows of financial figures: high-growth net profits can’t hide structural risks

According to disclosures in the prospectus, Synutra Dairy’s operating revenue from 2023 to 2025 was RMB 10.99B, RMB 10.67B, and RMB 11.23B respectively, with a three-year compound annual growth rate of only 1.1%. This means that over the past three years, Synutra Dairy’s revenue scale has barely gone anywhere.

In stark contrast to the sluggish revenue growth, net profit over the same period rose from RMB 438 million to RMB 754 million, with a compound annual growth rate as high as 31.3%, and its net profit margin improved from 4% to 6.7%. At first glance, this “profit performance divergence” looks impressive, but digging deeper reveals a hidden trick.

The high growth in profits is mainly driven by adjustments to product mix.

Synutra Dairy focuses on low-temperature liquid dairy products with high gross margins. The revenue contribution of this segment increased from 44.8% in 2023 to 53.8% in 2025, with a gross margin of about 36%, far higher than the 23% gross margin of room-temperature products. However, how long can this strategy of “trading profit for scale” be sustained amid fierce market competition? A big question mark needs to be placed over it.

More alarming is that Synutra Dairy’s accounts receivable problems have already surfaced.

At the end of 2025, Synutra Dairy’s accounts receivable totaled RMB 648 million, up about 7% year over year, accounting for roughly 90% of net profit attributable to shareholders in the same period.

According to a report by Beijing Business Today, senior dairy industry analyst Song Liang said this is related to its DTC (direct-to-consumer) business model that it has been pushing aggressively. Shifting from the traditional dealer model where cash is settled on a current basis to direct retail delivery lengthens the payment cycle, making cash flow tight. Shen Meng, Executive Director at Shanson Capital, even said bluntly that for a fast-moving consumer goods company, such a high proportion of receivables may indicate that the products are not selling well in the dealer channel, causing dealers to struggle with cash flow and be unable to collect payments on time.

Liabilities are another sword hanging over Synutra Dairy’s head.

Although the asset-liability ratio has fallen from nearly 70% in 2022 to 57% by the end of 2025, it is still relatively high within the dairy products industry. At the end of 2025, in the liability structure, short-term borrowings were RMB 444 million, while non-current liabilities due within one year were as high as RMB 1.37B, and long-term borrowings were RMB 564 million. Also according to a report by Dawang Finance Information, Synutra Dairy’s interest-bearing liabilities totaled more than RMB 2.38B at the end of 2025. Each year, interest expenses are nearly RMB 80 million, continuously eroding profits. At the same period-end, Synutra Dairy had only RMB 355 million in cash and cash equivalents on its books, which is no longer sufficient to cover short-term borrowings—making short-term repayment pressure self-evident.

What is perhaps most worrying is goodwill of nearly RMB 1 billion, representing about 11% of total assets. This large amount of goodwill mainly comes from the acquisition in 2020 of Ningxia Huanmei Dairy Development Co., Ltd. and its subsidiaries, totaling RMB 831 million. The auditing institution has classified it as a “key audit matter,” warning of potential impairment risk.

Once the acquired assets fail to meet performance expectations, an impairment of such a large goodwill balance would directly hit Synutra Dairy’s income statement. Frequent acquisitions may have quickly pushed Synutra Dairy into the “billion-yuan club,” but it also left lingering issues of high goodwill and high liabilities. Today, those issues have become a heavy burden for its capital market.

02

Growth losing momentum and a competitive dilemma: the pain of national expansion under the “FreshCube” strategy

Synutra Dairy centers on the “FreshCube strategy,” trying to break through in the low-temperature track with differentiation. However, its path to national expansion has been extremely difficult, with serious imbalances in regional growth.

According to its 2025 financial report, in the Southwest region—its home base—revenue was RMB 3.83 billion, with year-over-year growth nearly at a standstill, only 0.04%; revenue in the Northwest region was RMB 1.27B, equal to the previous year.

Synutra Dairy’s main incremental market is the East China region. Although revenue there grew year over year by nearly 15% to RMB 3.52B, the number of its distributors in that region dropped sharply from 1,051 to 785, a net decrease of 266, shrinking by more than 25%. In 2025, the total number of Synutra Dairy’s distributors fell from 3,461 to 3,078, a net decrease of 383, for an overall shrinkage of 11%. In response, Synutra Dairy only explained that the number of distributors in North China decreased by 31.6% as “optimizing tail-end distributors with low output and insufficient contribution,” but it did not explain the contraction in other regions. The large-scale loss of distributors—was it an active optimization of channels, or did declining market competitiveness force a passive exit? That is worth thinking deeply about.

This paradox of “regional growth while channels shrink” stems from Synutra Dairy’s distinctive development model.

Synutra Dairy rapidly expands by acquiring brands of a dozen or so local dairy enterprises and allows them to operate independently. The advantage of this model is that it can quickly obtain channels and brand recognition in regional markets. But the disadvantages are equally obvious: brand synergy is hard to form; consumers’ recognition of the “Synutra Dairy” parent company is low; marketing resources are scattered, making it unfavorable to build a national brand.

Synutra Dairy has multiple brands under it, such as “24-Hour,” “Asahi Vip,” “Today’s Fresh Milk Shop,” “Beginning Heart,” and others, but so far it has not managed to create national low-temperature dairy “hero products” like Junlebao’s “Yuexianhuo” or Bright Dairy’s “Beiyou.” The lack of a strong unified brand and breakout products makes it look less capable when facing nationwide giants.

At the same time, industry giants are moving in with heavy reinforcements. After Yili and Mengniu saw growth peak in the room-temperature milk market, they have been accelerating their deployment in low-temperature milk and regional markets. With strong financial strength and channel networks, they can even subsidize low-temperature products using profits from their room-temperature business, using price wars to capture market share.

Facing the frequent promotional offensives in offline supermarkets and department stores from Yili’s Jindian, Mengniu’s Meiri Xianyu, and Junlebao’s Yuexianhuo, Synutra Dairy has had to significantly increase marketing spending to maintain market share. In 2025, Synutra Dairy’s selling expenses rose year over year by 9.05% to RMB 1.81 billion, with a growth rate higher than revenue growth. Of that, advertising and promotional expenses reached RMB 316 million, with growth exceeding 30%.

Looking across a longer time horizon, Synutra Dairy’s selling expense ratio rose from 14% in 2022 to 16% in 2025, reflecting a decline in its brand competitiveness and reduced marketing conversion efficiency. It has fallen into a vicious cycle of “the more it promotes, the more growth lacks momentum.”

03

Doubts about the IPO motive: is it an international blueprint, or an unwilling “capital infusion” move?

In its announcements, Synutra Dairy claims that listing in Hong Kong is to “promote an internationalization strategy, build an international capital operation platform, and enhance the company’s capital strength.” However, given its financial situation, the market is more inclined to believe that this is a passive choice made to relieve debt pressure and satisfy funding needs for acquisitions.

In terms of funding needs, Synutra Dairy faces urgent repayment pressure. In addition to high short-term liabilities, Synutra Dairy also faces redemption pressure from its “Synutra Dairy Convertible Bonds.” In 2025, Synutra Dairy’s net cash flow from fundraising activities was negative RMB 1.09 billion, down 12.33% year over year. As bank borrowing contracted and A-share refinancing channels may be limited, it turned to Hong Kong share financing to fill the funding gap. The stated use of proceeds in this IPO—“for working capital and other general corporate purposes”—also directly reveals its need to replenish liquidity.

Even if the listing succeeds, Synutra Dairy’s outlook in the Hong Kong market is still not optimistic.

First, in Hong Kong, the valuation framework for consumer stocks is generally lower than in A shares. In recent years, even consumption leaders such as Haitian Flavor and Dongpeng Beverage that listed in Hong Kong have still been unable to escape the fate of price declines after listing and long-term discounts on share prices. For Synutra Dairy, whose industry position is in the second tier and where the growth story is not particularly compelling, the risk of “valuation discount” is even greater.

Second, the Hong Kong market is highly institutionalized, and investors place extreme importance on corporate governance. The capital layout of Liu Yonghao’s family, the company’s actual controller, is complex. Past frequent related-party transactions and capital operations may be viewed by overseas long-term funds as serious “principal-agent risk.”

In addition, the Hong Kong Stock Exchange’s requirements regarding ESG disclosures, related-party transactions, and corporate governance are stricter than those of A shares. This will bring Synutra Dairy higher compliance costs and greater operational uncertainty.

Its claimed “internationalization strategy” also appears to have weak foundations.

In the domestic market, with its nationwide expansion struggling amid stagnation in core areas and the dilemma of distributor losses, how can it talk about globalization? The prospectus mentions that it will assess overseas market opportunities, but the specific plan is vague. Its recent collaboration with dairy companies in Hong Kong looks more like a small-scale business trial, not a clear internationalization path. Against the backdrop that giants such as Yili and Mengniu have already gone overseas and established some advantages, Synutra Dairy’s internationalization narrative lacks convincing force.

Conclusion

Behind Synutra Dairy’s push for the halo of becoming the first “A+H” dairy company, there are multiple predicaments: weak growth, high liabilities, and intensifying competition. Its Hong Kong IPO is more like a capital “capital injection” done out of necessity, in a context where A-share refinancing is restricted and short-term repayment pressure is high.

Although the low-temperature track still has growth potential, given the downward pressure from nationwide giants, obstacles in its own national expansion progress, and the high risk of goodwill impairment, Synutra Dairy’s “FreshCube” strategy is facing a severe test.

Perhaps only when Synutra Dairy truly solves its intrinsic growth model and financial health issues can its capital market story have a solid underlying foundation. Otherwise, listing in Hong Kong may only temporarily shift the problems from the A-share market, rather than providing a fundamental solution.

As for where Synutra Dairy will go in the future, Bofang Finance will continue to follow developments.

Author statement: personal opinion, for reference only